Literature DB >> 2999452

Activity of the cytomegalovirus genome in the presence of PPi analogs.

B Wahren, U Rudén, H Gadler, B Oberg, B Eriksson.   

Abstract

PPi analogs and esters of these were studied for their effect on cytomegalovirus (CMV) multiplication. Five aromatic monoesters of phosphonoformate esterified either in the phosphono or the carboxylic group and two diesters were demonstrated to inhibit CMV DNA synthesis and late viral protein synthesis. In a direct assay, the monoesters but not the diesters inhibited CMV DNA polymerase activity. The production of early CMV antigens was not inhibited by any of the compounds. After incubation with either drug for periods up to 7 days, renewed viral production occurred on withdrawal of the compound. All inhibitory esters as well as PPi analogs showed a CMV multiplicity dependence. This was demonstrated both for CMV strain Ad.169 and for all tested CMV isolates. Evidence was found that the esters are hydrolyzed to phosphonoformate and, therefore, may be of importance as useful prodrugs in the specific therapy of CMV infections. The general phenomenon of reversibility to the productive state and the multiplicity dependence of CMV are important factors in any treatment schedule.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2999452      PMCID: PMC252674     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  24 in total

1.  Inhibition of herpes simplex virus infection in tissue culture by trisodium phosphonoformate.

Authors:  B Svennerholm; A Vahlne; E Lycke
Journal:  Proc Soc Exp Biol Med       Date:  1979-06

2.  Human cytomegalovirus. III. Virus-induced DNA polymerase.

Authors:  E S Huang
Journal:  J Virol       Date:  1975-08       Impact factor: 5.103

3.  Antiviral potential of phosphonoacetic acid.

Authors:  L R Overby; R G Duff; J C Mao
Journal:  Ann N Y Acad Sci       Date:  1977-03-04       Impact factor: 5.691

Review 4.  The antiherpesvirus action of phosphonoacetate.

Authors:  J A Boezi
Journal:  Pharmacol Ther       Date:  1979       Impact factor: 12.310

5.  Human cytomegalovirus. IV. Specific inhibition of virus-induced DNA polymerase activity and viral DNA replication by phosphonoacetic acid.

Authors:  E S Huang
Journal:  J Virol       Date:  1975-12       Impact factor: 5.103

6.  Inhibition of cytomegalovirus late antigens by phosphonoformate.

Authors:  B Wahren; B Oberg
Journal:  Intervirology       Date:  1980       Impact factor: 1.763

7.  Cytomegalovirus DNA polymerase inhibition and kinetics.

Authors:  B Wahren; B Eriksson
Journal:  Adv Enzyme Regul       Date:  1985

8.  Mechanism of phosphonoacetate inhibition of herpesvirus-induced DNA polymerase.

Authors:  S S Leinbach; J M Reno; L F Lee; A F Isbell; J A Boezi
Journal:  Biochemistry       Date:  1976-01-27       Impact factor: 3.162

9.  Reversible inhibition of cytomegalovirus replication by phosphonoformate.

Authors:  B Wahren; B Oberg
Journal:  Intervirology       Date:  1980       Impact factor: 1.763

10.  Pyrophosphate analogues as inhibitors of herpes simplex virus type 1 DNA polymerase.

Authors:  B Eriksson; A Larsson; E Helgstrand; N G Johansson; B Oberg
Journal:  Biochim Biophys Acta       Date:  1980-03-28
View more
  6 in total

1.  Pyrrolo[2,3-d]pyrimidine nucleosides as inhibitors of human cytomegalovirus.

Authors:  S R Turk; C Shipman; R Nassiri; G Genzlinger; S H Krawczyk; L B Townsend; J C Drach
Journal:  Antimicrob Agents Chemother       Date:  1987-04       Impact factor: 5.191

2.  Identification of amino acids in herpes simplex virus DNA polymerase involved in substrate and drug recognition.

Authors:  J S Gibbs; H C Chiou; K F Bastow; Y C Cheng; D M Coen
Journal:  Proc Natl Acad Sci U S A       Date:  1988-09       Impact factor: 11.205

3.  Acyclic guanosine analogs as inhibitors of human cytomegalovirus.

Authors:  B Wahren; A Larsson; U Rudén; A Sundqvist; E Sølver
Journal:  Antimicrob Agents Chemother       Date:  1987-02       Impact factor: 5.191

4.  Two specific topoisomerase II inhibitors prevent replication of human cytomegalovirus DNA: an implied role in replication of the viral genome.

Authors:  J D Benson; E S Huang
Journal:  J Virol       Date:  1988-12       Impact factor: 5.103

Review 5.  Foscarnet. A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis.

Authors:  P Chrisp; S P Clissold
Journal:  Drugs       Date:  1991-01       Impact factor: 9.546

Review 6.  Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections.

Authors:  A J Wagstaff; H M Bryson
Journal:  Drugs       Date:  1994-08       Impact factor: 9.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.